ALPHAMAB-B (09966) saw its share price rise over 8% during the trading session. As of the latest update, the stock was up 7.06%, trading at HKD 10.01 with a turnover of HKD 23.12 million.

The company previously announced that the Phase I clinical study results for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of HER2-negative locally advanced or metastatic breast cancer, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings will be disclosed in a poster presentation during the conference.

Furthermore, significant results from the Phase III clinical study of anitumab (KN026), a HER2 bispecific antibody developed in collaboration with a wholly-owned subsidiary of CSPC Pharmaceutical Group, combined with CSPC's albumin-bound docetaxel (HB1801) for the neoadjuvant treatment of breast cancer, have been successfully selected for the "Late-Breaking Abstract" (LBA) session at the 2026 ASCO Annual Meeting.

The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA.